Want to see KR:228760 full AI Analyst Report?

Genomictree, Inc. (228760) Price & Analysis

― Followers

228760 Stock Chart & Stats

₩9900.00

-₩500.00(-4.81%)

Oct 29, 2026

―

Day’s Range― - ―

52-Week Range₩8,790.00 - ₩33,300.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)105.86K

Market Cap

₩242.55B

Enterprise Value₩187.37B

Total Cash (Recent Filing)₩75.39B

Total Debt (Recent Filing)₩55.19M

Price to Earnings (P/E)―

Beta0.09

Next Earnings

Nov 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-334.06

Shares Outstanding24,859,201

10 Day Avg. Volume85,716

30 Day Avg. Volume105,855

Financial Highlights & Ratios

PEG Ratio3.41

Price to Book (P/B)3.59

Price to Sales (P/S)109.82

P/FCF Ratio-41.42

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-145

Revenue Forecast (FY)₩7.80B

Bulls Say, Bears Say

Bulls Say

Low LeverageThe very low debt burden limits refinancing pressure and preserves financial flexibility while Genomictree continues investing in research and development. A sizable equity base provides a meaningful cushion against operating volatility and gives management more capacity to fund initiatives without relying heavily on external borrowing.

Improved Gross MarginThe return to a slightly positive gross margin suggests that the underlying diagnostic offerings may be generating better direct economics than in the prior two years. Although profitability remains insufficient, further improvement could support operating leverage if revenue stabilizes and fixed costs are better absorbed.

Specialized Diagnostics PlatformGenomictree operates in a specialized molecular diagnostics niche built around genomic and DNA-methylation biomarkers. This creates a focused platform for developing tests and related clinical solutions, with potential to support recurring commercial opportunities as validated diagnostics gain use in laboratories and clinical settings.

Bears Say

Persistent Operating LossesDeeply negative operating and net margins indicate that current revenue levels do not cover the company’s cost base. Unless margin improvement becomes substantial and sustained, continued losses can consume equity, restrict reinvestment capacity, and delay the point at which the diagnostics platform can fund itself.

Weak Cash GenerationOngoing negative operating and free cash flow means Genomictree is consuming rather than generating internal funding. This increases reliance on existing cash reserves or future financing to support research, commercialization, and overhead, leaving less flexibility if losses persist or funding conditions become less favorable.

Volatile Revenue TrendThe revenue pattern lacks consistent growth, with the 2025 rebound remaining modest after two years of contraction. Such volatility makes planning and fixed-cost absorption more difficult, weakens confidence in scalable commercialization, and raises the risk that improved gross margin will not translate into sustainable earnings.

Genomictree, Inc. News

Genomictree Plans Two-Day IR Roadshow for Institutional Investors in Seoul

Genomictree, Inc. ( ($KR:228760) ) has shared an announcement. Genomictree, Inc. will hold a two-day corporate investor relations...

2M ago

228760 FAQ

What was Genomictree, Inc.’s price range in the past 12 months?

Genomictree, Inc. lowest stock price was ₩8790.00 and its highest was ₩33300.00 in the past 12 months.

What is Genomictree, Inc.’s market cap?

Genomictree, Inc.’s market cap is ₩242.55B.

When is Genomictree, Inc.’s upcoming earnings report date?

Genomictree, Inc.’s upcoming earnings report date is Nov 06, 2026 which is in 7 days.

How were Genomictree, Inc.’s earnings last quarter?

Genomictree, Inc. released its earnings results on Aug 07, 2026. The company reported -₩100.585 earnings per share for the quarter.

Is Genomictree, Inc. overvalued?

According to Wall Street analysts Genomictree, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Genomictree, Inc. pay dividends?

Genomictree, Inc. does not currently pay dividends.

What is Genomictree, Inc.’s EPS estimate?

Genomictree, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Genomictree, Inc. have?

Genomictree, Inc. has 24,859,201 shares outstanding.

What happened to Genomictree, Inc.’s price movement after its last earnings report?

Genomictree, Inc. reported an EPS of -₩100.585 in its last earnings report. Following the earnings report the stock price went down -2.458%.

Which hedge fund is a major shareholder of Genomictree, Inc.?

Currently, no hedge funds are holding shares in KR:228760

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Genomictree, Inc.

Genomictree Inc is a molecular diagnostics firm focused on innovating technologies that address critical, unmet demands within the healthcare industry.